Tax Season is Here! Save 15% on H&R Block Online
iconAll times are GMT -4. The time now is 07:01 PM. | Search:

» StockRants Stock Forum » Public Stock Forums » US Stock Picks » Strong Buy: BXRX =MC $51 M --FDA Decision in Q1 for a Big Drug



Reply
 
Thread Tools Search this Thread
Old 12-20-2019, 10:05 AM   Nav to Top  #1
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 283
Favorites: Aapl celg onxx
Rep Power: 111
Reputation: 36
Biohero is on a distinguished road
Default BXRX =MC $51 M --FDA Decision in Q1 for a Big Drug

Market-Cap $51 Million-- Cash $19 Million or untill end 2020 -- Shares Out 9.1 Million -- Potential FDA approval for their lead drug Anjeso (non-opioid pain reliever ) in Q1 2020 which has HUGE market potential .MASSIVE underpriced and undiscovered low float stock with significant upside potential here ..Could run to $10+ ahead of the FDA decision and much higher on approval .GL


Baudax Bio (BXRX)

Market Cap 51 M
Cash $19 M
Price $5.60

Shares Out 9.1 M



New Presentation (december 2019)
https://d1io3yog0oux5.cloudfront.net...NAL%281%29.pdf



Janney starts Baudax Bio at buy; fair value estimate $12
https://biotuesdays.com/2019/11/22/j...e-estimate-12/

Baudax’s key product is Anjeso, a long-acting intravenous formulation of meloxicam, an established non-opioid pain reliever, available through an oral formulation. “We see a high probability of FDA approval in the first quarter of 2020, which would be a meaningful catalyst to drive the stock towards our fair value,” writes analyst Ester Hong.

She estimates peak U.S. sales of $355-million for Anjeso but sees “upside from increased demand for a potent non-opioid that allows patients to recover and go home faster.”




Biohero is offline   Rate this post Yes | No Reply With Quote
Old 01-22-2020, 09:51 AM   Nav to Top  #2
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 283
Favorites: Aapl celg onxx
Rep Power: 111
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

Great News out today ....FDA DECISION NEXT MONTH

(FDA) has set a PDUFA goal date of February 20, 2020
https://finance.yahoo.com/news/bauda...120010357.html
Biohero is offline   Rate this post Yes | No Reply With Quote
Old 01-24-2020, 03:19 PM   Nav to Top  #3
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 283
Favorites: Aapl celg onxx
Rep Power: 111
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

Any dip here is a great buying opp ahead of the FDA decision next month ,stock likely tohit $10 in the coming days .GL
Biohero is offline   Rate this post Yes | No Reply With Quote
Old 01-27-2020, 02:19 PM   Nav to Top  #4
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 283
Favorites: Aapl celg onxx
Rep Power: 111
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

FDA approval is very likely this time ,, Approval would make this undiscovered stock worth more than $50 per share

https://ir.recropharma.com/press-rel...xicam-new-drug

"The FDA’s letter states that the appeal was granted “specific to the request…that the NDA provides sufficient evidence of effectiveness and safety to support approval.” The letter also states that “before IV meloxicam can be approved and legally marketed, agreed-upon labeling (prescribing information) must be negotiated with the Division.”
Biohero is offline   Rate this post Yes | No Reply With Quote
Old 02-03-2020, 11:56 AM   Nav to Top  #5
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 283
Favorites: Aapl celg onxx
Rep Power: 111
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

17 days till FDA decision ,,, still a great buying opportunity here
Biohero is offline   Rate this post Yes | No Reply With Quote
Old 02-21-2020, 04:34 PM   Nav to Top  #6
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 283
Favorites: Aapl celg onxx
Rep Power: 111
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

Still a massive buying opportunity after FDA approval at current laughable valuation of only $87 million

Baudax Bio's (BXRX) Non-opioid Pain Drug Makes It To The Finish Line ...
https://www.rttnews.com/3071353/baud...aspx?refresh=1


ANJESO that will be administered as a once-a-day intravenous (IV) bolus push is the only available 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) and offers once-daily dosing.

Baudax expects ANJESO to be available in the U.S. in late April or early May 2020.

Esther Hong, an analyst at Janney Montgomery, estimates peak sales of the drug in the U.S. to reach about $355 million.
Biohero is offline   Rate this post Yes | No Reply With Quote
Reply

Similar Threads
Thread Thread Starter Forum Replies Last Post
Buy: TRL.TO (MC $83 M) FDA DECISION ON MAY 28 = 200% Potential !!!!! Biohero Canadian Stock Picks 0 05-20-2014 10:09 AM
Yen Weakens Before BOJ Decision FxTT Forex Trading 0 04-10-2012 08:54 AM
Another 2nd Rate Decision dodjit Traders Lounge 0 09-10-2009 04:29 AM
Spec: NGSX - FDA decision date 8/16/09 kabilius US Stock Picks 1 08-05-2009 06:58 PM
Watch: Food / drug approval decision dates kabilius US Stock Picks 29 07-14-2009 10:13 PM


Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On